Treatment of Choroidal Subretinal Neovascularization against Immune Response
$139,327N01FY2009EYNIH
The Emmes Company, Llc, Rockville MD
Investigators
Abstract
This study will examine whether the anti-inflammatory medicines infliximab, sirolimus or daclizumab, when given with a patient's current therapies, will prevent the growth of new blood vessels in the eye in patients with age-related macular degeneration (AMD).
View original record on NIH RePORTER →